Literature DB >> 26762873

T1-Mapping and Outcome in Nonischemic Cardiomyopathy: All-Cause Mortality and Heart Failure.

Valentina O Puntmann1, Gerry Carr-White2, Andrew Jabbour3, Chung-Yao Yu3, Rolf Gebker4, Sebastian Kelle4, Rocio Hinojar5, Adelina Doltra4, Niharika Varma6, Nicholas Child6, Toby Rogers7, Gonca Suna8, Eduardo Arroyo Ucar9, Ben Goodman9, Sitara Khan8, Darius Dabir10, Eva Herrmann11, Andreas M Zeiher12, Eike Nagel13.   

Abstract

OBJECTIVES: The study sought to examine prognostic relevance of T1 mapping parameters (based on a T1 mapping method) in nonischemic dilated cardiomyopathy (NIDCM) and compare them with conventional markers of adverse outcome.
BACKGROUND: NIDCM is a recognized cause of poor clinical outcome. NIDCM is characterized by intrinsic myocardial remodeling due to complex pathophysiological processes affecting myocardium diffusely. Lack of accurate and noninvasive characterization of diffuse myocardial disease limits recognition of early cardiomyopathy and effective clinical management in NIDCM. Cardiac magnetic resonance (CMR) supports detection of diffuse myocardial disease by T1 mapping.
METHODS: This is a prospective observational multicenter longitudinal study in 637 consecutive patients with dilated NIDCM (mean age 50 years [interquartile range: 37 to 76 years]; 395 males [62%]) undergoing CMR with T1 mapping and late gadolinium enhancement (LGE) at 1.5-T and 3.0-T. The primary endpoint was all-cause mortality. A composite of heart failure (HF) mortality and hospitalization was a secondary endpoint.
RESULTS: During a median follow-up period of 22 months (interquartile range: 19 to 25 months), we observed a total of 28 deaths (22 cardiac) and 68 composite HF events. T1 mapping indices (native T1 and extracellular volume fraction), as well as the presence and extent of LGE, were predictive of all-cause mortality and HF endpoint (p < 0.001 for all). In multivariable analyses, native T1 was the sole independent predictor of all-cause and HF composite endpoints (hazard ratio: 1.1; 95% confidence interval: 1.06 to 1.15; hazard ratio: 1.1; 95% confidence interval: 1.05 to 1.1; p < 0.001 for both), followed by the models including the extent of LGE and right ventricular ejection fraction, respectively.
CONCLUSIONS: Noninvasive measures of diffuse myocardial disease by T1 mapping are significantly predictive of all-cause mortality and HF events in NIDCM. We provide a basis for a novel algorithm of risk stratification in NIDCM using a complementary assessment of diffuse and regional disease by T1 mapping and LGE, respectively.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  T1 mapping; heart failure; late gadolinium enhancement; native T1; nonischemic cardiomyopathy; survival

Mesh:

Year:  2016        PMID: 26762873     DOI: 10.1016/j.jcmg.2015.12.001

Source DB:  PubMed          Journal:  JACC Cardiovasc Imaging        ISSN: 1876-7591


  104 in total

1.  MRI T1 Mapping in Hypertrophic Cardiomyopathy: Evaluation in Patients Without Late Gadolinium Enhancement and Hemodynamic Obstruction.

Authors:  Jing Xu; Baiyan Zhuang; Arlene Sirajuddin; Shuang Li; Jinghan Huang; Gang Yin; Lei Song; Yong Jiang; Shihua Zhao; Minjie Lu
Journal:  Radiology       Date:  2019-11-26       Impact factor: 11.105

2.  ESC sudden-death risk model in hypertrophic cardiomyopathy: Incremental value of quantitative contrast-enhanced CMR in intermediate-risk patients.

Authors:  Rocio Hinojar; José Luis Zamorano; Ariana Gonzalez Gómez; Maria Plaza Martin; Amparo Esteban; Luis Miguel Rincón; Juan Carlos Portugal; José Julio Jimenez Nácher; Covadonga Fernández-Golfín
Journal:  Clin Cardiol       Date:  2017-06-14       Impact factor: 2.882

3.  Native T1 value in the remote myocardium is independently associated with left ventricular dysfunction in patients with prior myocardial infarction.

Authors:  Shiro Nakamori; Javid Alakbarli; Steven Bellm; Shweta R Motiwala; Gifty Addae; Warren J Manning; Reza Nezafat
Journal:  J Magn Reson Imaging       Date:  2017-02-02       Impact factor: 4.813

4.  Increased myocardial native T1 relaxation time in patients with nonischemic dilated cardiomyopathy with complex ventricular arrhythmia.

Authors:  Shiro Nakamori; An H Bui; Jihye Jang; Hossam A El-Rewaidy; Shingo Kato; Long H Ngo; Mark E Josephson; Warren J Manning; Reza Nezafat
Journal:  J Magn Reson Imaging       Date:  2017-07-24       Impact factor: 4.813

Review 5.  Advances in MRI Applications to Diagnose and Manage Cardiomyopathies.

Authors:  Ramya Vajapey; Brendan Eck; Wilson Tang; Deborah H Kwon
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-27

6.  Myocardial native-T1 times are elevated as a function of hypertrophy, HbA1c, and heart rate in diabetic adults without diffuse fibrosis.

Authors:  Bonnie Lam; Tori A Stromp; Zhengxiong Hui; Moriel Vandsburger
Journal:  Magn Reson Imaging       Date:  2019-05-21       Impact factor: 2.546

7.  The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure.

Authors:  Mark A Peterzan; Oliver J Rider; Lisa J Anderson
Journal:  Card Fail Rev       Date:  2016-11

8.  Contrast-enhanced T1 mapping-based extracellular volume fraction independently predicts clinical outcome in patients with non-ischemic dilated cardiomyopathy: a prospective cohort study.

Authors:  Jong-Chan Youn; Yoo Jin Hong; Hye-Jeong Lee; Kyunghwa Han; Chi Young Shim; Geu-Ru Hong; Young Joo Suh; Jin Hur; Young Jin Kim; Byoung Wook Choi; Seok-Min Kang
Journal:  Eur Radiol       Date:  2017-04-24       Impact factor: 5.315

Review 9.  Myocardial T1 and ECV Measurement: Underlying Concepts and Technical Considerations.

Authors:  Austin A Robinson; Kelvin Chow; Michael Salerno
Journal:  JACC Cardiovasc Imaging       Date:  2019-09-18

10.  Myocardial T1 Measurement Predicts Beneficial LV Remodeling After Long-Term Heart Failure Therapy.

Authors:  William S Bradham; Susan P Bell; Douglas W Adkisson; Holly M Smith; Frank E Harrell; Mark A Lawson; Henry Ooi; Douglas B Sawyer; Marvin W Kronenberg
Journal:  J Card Fail       Date:  2016-12-08       Impact factor: 5.712

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.